Open AccessExperimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)
Author(s) -
Ritu Sharma,
David J. Harrison,
Dorothy Kisielewski,
Diane Cassidy,
Alison D. McNeilly,
Jennifer Gallagher,
Shaun Walsh,
Tadashi Honda,
Rory J. McCrimmon,
Albena T. DinkovaKostova,
Michael L.J. Ashford,
John Dillon,
John D. Hayes
Publication year - 2017
Publication title -
cellular and molecular gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.417
H-Index - 38
ISSN - 2352-345X
DOI - 10.1016/j.jcmgh.2017.11.016
Subject(s) - steatosis , endocrinology , medicine , oxidative stress , insulin resistance , fibrosis , lipogenesis , inflammation , steatohepatitis , chemistry , fatty liver , biology , insulin , lipid metabolism , disease
Nonalcoholic steatohepatitis (NASH) is associated with oxidative stress. We surmised that pharmacologic activation of NF-E2 p45-related factor 2 (Nrf2) using the acetylenic tricyclic bis(cyano enone) TBE-31 would suppress NASH because Nrf2 is a transcriptional master regulator of intracellular redox homeostasis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom